TG Therapeutics is executing strongly on the commercial launch of Briumvi, with revenue accelerating 87.3% year-over-year to $616M TTM and sequential growth of 70.3% in 2026Q2. However, investors should monitor gross margin erosion (down 840bps to 82.9% since ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue surged 87.3% year-over-year to $616M TTM, with sequential growth accelerating to 70.3% in 2026Q2, but gross margin contracted 840bps to 82.9% from 2024Q1, indicating pricing pressure.
Comprehensive stock analysis, price targets, and earnings estimates are readily available for informed investment decisions.
Real-time stock price, charts, and key statistics provide up-to-date information for investors.
Regular news updates and headlines keep investors informed about the latest developments.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | $0.05-83.6% vs $0.31 | $240M+4.6% vs $230M |
Q2 2026 May 6, 2026 | $0.14-39.1% vs $0.23 | $205M+2.3% vs $200M |
Q1 2026 Feb 26, 2026 | $0.14-60.0% vs $0.35 | $193M+0.4% vs $192M |
Q4 2025 Nov 3, 2025 | $2.43+912.5% vs $0.24 | $162M-16.6% vs $194M |
California State Teachers Retirement System lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 5,233.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 9,374,083 shares of the biopharmaceutical company's stock after acquiring an additional 9,198,333 shares during the period. California State Teachers
Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
Benchmark TGTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for TG Therapeutics, Inc. (TGTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $58.11 | $8.9B | 20.98 | 87.32% | 72.56% | 102.75% | — | |
| $26.87 | $3.38B | -8.17 | -4.26% | -386.32% | -87.98% | — | |
| $37.29 | $7.7B | -13.46 | — | -7585.86% | -69.59% | — | |
| $300.65 | $8.38B | -22.30 | -100% | — | -34.15% | — | |
| $122.06 | $10.04B | -33.08 | -16.72% | -285.41% | -21.5% | — | |
| $514.99 | $130.71B | 33.62 | 9.57% | 34.89% | 23.31% | — |
TG Therapeutics, Inc. (TGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
TG Therapeutics, Inc. (TGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jun 12, 2026·SEC
Jun 3, 2026·SEC
Get notified when TGTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TG Therapeutics, Inc. (TGTX) stock FAQ — growth, dividends, profitability & financials explained
TG Therapeutics, Inc. (TGTX) reported $799.5M in revenue for fiscal year 2025. This represents a 799436% increase from $0.1M in 1996.
TG Therapeutics, Inc. (TGTX) grew revenue by 87.3% over the past year. This is strong growth.
Yes, TG Therapeutics, Inc. (TGTX) is profitable, generating $441.5M in net income for fiscal year 2025 (72.6% net margin).
TG Therapeutics, Inc. (TGTX) has a return on equity (ROE) of 102.8%. This is excellent, indicating efficient use of shareholder capital.
TG Therapeutics, Inc. (TGTX) had negative free cash flow of $0.6M in fiscal year 2025, likely due to heavy capital investments.
